You are here: Industry Insights > ICR

News List

cancer patients miss out on innovative new treatments pharmatimes
February 07, 2022
Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes.
Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients pharmatimes
July 27, 2021
A four-drug combination therapy has shown significant benefit for patients with newly diagnosed myeloma, according to a new analysis led by researchers from The Institute of Cancer Research, London (ICR).
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR pharmatimes
July 16, 2021
The National Institute of Health and Care Excellence (NICE) has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.
Scientists identify link between genetic changes and rare childhood cancer rhabdomyosarcoma pharmatimes
June 28, 2021
Genetic changes may help to improve decision making for the treatment of the rare and aggressive form of childhood cancer rhabdomyosarcoma, according to a new international study led by researchers at the Institute of Cancer Research, London (ICR).
Researchers find CD38-targeting drugs may show promise against prostate cancer pharmatimes
May 11, 2021
A new study suggests that drugs which target the CD38 protein molecule may show promise against prostate cancer by ‘reawakening’ the body’s immune response against this tumour type.
PARP inhibitors could exploit weaknesses in a range of cancers pharmatimes
April 26, 2021
PARP inhibitors – a type of drug most commonly used to treat ovarian and breast cancers – could offer a new way of targeting a range of cancers with a particular gene defect in the PBRM1 gene, according to researchers.
Experts call for advanced radiotherapy funding to address COVID-19 cancer care backlog pharmatimes
April 13, 2021
The Institute for Cancer Research, London (ICR) is urging the government to invest in advanced radiotherapy in a bid to address the backlog in NHS cancer care that has accumulated during the COVID-19 pandemic.
Cancer research in the UK faces ‘perfect storm’ of funding cuts pharmatimes
April 01, 2021
The Institute of Cancer Research, London (ICR) has made an appeal to Prime Minister Boris Johnson after identifying a ‘perfect storm’ of funding cuts that could impact cancer research in the UK.
ICR’s ‘resistance-busting’ drug advances into Phase I trial pharmatimes
March 19, 2021
The Institute of Cancer Research, London (ICR) has announced that its ‘resistance-busting’ drug EP0042 has entered a Phase I clinical trial in patients with cancers including acute myeloid leukaemia (AML).
Researchers identify existing drug’s potential for triple negative breast cancer pharmatimes
January 29, 2021
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).

Previous page 1 2 3 Next page